C. Massard

428 total citations
40 papers, 325 citations indexed

About

C. Massard is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, C. Massard has authored 40 papers receiving a total of 325 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 13 papers in Cancer Research. Recurrent topics in C. Massard's work include Cancer Genomics and Diagnostics (8 papers), Prostate Cancer Treatment and Research (6 papers) and Lung Cancer Treatments and Mutations (4 papers). C. Massard is often cited by papers focused on Cancer Genomics and Diagnostics (8 papers), Prostate Cancer Treatment and Research (6 papers) and Lung Cancer Treatments and Mutations (4 papers). C. Massard collaborates with scholars based in France, United Kingdom and Austria. C. Massard's co-authors include Jean‐Charles Soria, Nicolas Magné, Olivier Hermine, Colin D. Mansfield, Alain Moussy, P. Armand, Jean‐Yves Blay, B. Bui, J.C. Soria and Yohann Loriot and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

C. Massard

35 papers receiving 319 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Massard France 11 141 130 87 55 47 40 325
Daniela Bärtschi Switzerland 5 156 1.1× 141 1.1× 132 1.5× 81 1.5× 17 0.4× 6 292
Susan M. Flick United States 6 113 0.8× 72 0.6× 132 1.5× 24 0.4× 58 1.2× 6 370
Stephen Brincat United States 7 195 1.4× 233 1.8× 238 2.7× 68 1.2× 22 0.5× 9 478
Yasuo Kodera Japan 8 167 1.2× 120 0.9× 167 1.9× 64 1.2× 9 0.2× 14 405
So Young Rha South Korea 5 151 1.1× 111 0.9× 181 2.1× 52 0.9× 15 0.3× 8 433
Arya Mariam Roy United States 10 114 0.8× 87 0.7× 170 2.0× 79 1.4× 38 0.8× 74 355
T. Christopher Windham United States 7 203 1.4× 110 0.8× 177 2.0× 35 0.6× 35 0.7× 14 438
Jason L. Rowand United States 5 251 1.8× 80 0.6× 125 1.4× 62 1.1× 13 0.3× 6 369
Magdalena Benetkiewicz France 14 139 1.0× 104 0.8× 159 1.8× 110 2.0× 5 0.1× 18 413
Stefan Paul Moenig Germany 9 90 0.6× 102 0.8× 143 1.6× 64 1.2× 8 0.2× 21 300

Countries citing papers authored by C. Massard

Since Specialization
Citations

This map shows the geographic impact of C. Massard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Massard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Massard more than expected).

Fields of papers citing papers by C. Massard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Massard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Massard. The network helps show where C. Massard may publish in the future.

Co-authorship network of co-authors of C. Massard

This figure shows the co-authorship network connecting the top 25 collaborators of C. Massard. A scholar is included among the top collaborators of C. Massard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Massard. C. Massard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
O’Reilly, Séamus, Paloma Martín-Martorell, Maria‐Rosa Ghigna, et al.. (2024). 147O Scope of NUT carcinomas (NC): An international multicentric study. ESMO Open. 9. 102542–102542.
3.
Jones, Rhonda, Roman Groisberg, Jean‐Yves Blay, et al.. (2024). 1721MO Safety and efficacy of olutasidenib, an IDH1 mutant inhibitor, for the treatment of recurrent/relapsed or locally advanced or metastatic IDH1 mutated chondrosarcoma. Annals of Oncology. 35. S1031–S1032. 2 indexed citations
4.
Baldini, Capucine, Andreea Varga, Séverine Mouraud, et al.. (2021). 1732MO Pembrolizumab and nintedanib for patients with advanced mesothelioma. Annals of Oncology. 32. S1198–S1198.
5.
Vanacker, Hélène, Eric Angevin, Antoine Hollebecque, et al.. (2019). Enhanced performance of prognostic estimation from TCGA RNAseq data using transfer learning. Annals of Oncology. 30. v52–v52. 2 indexed citations
6.
Castañón, Eduardo, Valérie Dyevre, Sandrine Aspeslagh, et al.. (2017). Immunotherapy phase I trials in patients over 70 years with advanced solid tumours: The Gustave Roussy experience. Annals of Oncology. 28. v413–v413. 1 indexed citations
7.
Massard, C., Joaquı́n Mateo, Yohann Loriot, et al.. (2016). Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. Annals of Oncology. 28(1). 90–95. 20 indexed citations
8.
Kossaï, Myriam, Boris Duchemann, C. Boutros, et al.. (2015). Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy. Lung Cancer. 89(3). 306–310. 8 indexed citations
9.
Cany, Laurent, et al.. (2015). Enzalutamide and sleep apnea: an emerging central nervous system side-effect?. Annals of Oncology. 27(1). 206–206. 4 indexed citations
10.
Massard, C.. (2015). Enriching phase I trials with molecular alterations: Interim analysis of 708 patients enrolled in the MOSCATO 01. Annals of Oncology. 26. ii3–ii3. 6 indexed citations
11.
Even, Caroline, Ingrid Breuskin, E. Ileana, et al.. (2015). OC-014: Molecular screening for cancer treatment optimization in head and neck cancer (MOSCATO 01). Radiotherapy and Oncology. 114. 12–12. 1 indexed citations
12.
Hollebecque, Antoine, Éric Deutsch, C. Massard, et al.. (2013). A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma. Investigational New Drugs. 31(6). 1530–1538. 23 indexed citations
13.
Lorch, Anja, Caroline Mollévi, A. Kramar, et al.. (2010). Conventional-dose versus high-dose chemotherapy in relapsed or refractory male germ-cell tumors: A retrospective study in 1,594 patients.. Journal of Clinical Oncology. 28(15_suppl). 4513–4513. 9 indexed citations
14.
Besse, Benjamin, C. Massard, Vincent Haddad, et al.. (2010). ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy. Annals of Oncology. 22(3). 575–581. 14 indexed citations
15.
Loriot, Yohann, et al.. (2010). Outcome of patients with rare tumors included in phase l clinical trials.. Journal of Clinical Oncology. 28(15_suppl). e13109–e13109. 1 indexed citations
16.
Loriot, Yohann, Laurence Albiges‐Sauvin, Dimitrios Dionysopoulos, et al.. (2009). Why do residents choose the medical oncology specialty? Implications for future recruitment—results of the 2007 French Association of Residents in Oncology (AERIO) Survey. Annals of Oncology. 21(1). 161–165. 17 indexed citations
17.
Albiges‐Sauvin, Laurence, Antonin Lévy, C. Massard, & Karim Fizazi. (2009). Facteurs pronostiques et prédictifs du cancer de la prostate. Bulletin du Cancer. 96(4). 439–449. 5 indexed citations
18.
Albigès, Laurence, et al.. (2009). 7114 Interstitial pneumonitis during RAD-001 treatment: incidence by blinded radiological analysis. European Journal of Cancer Supplements. 7(2). 427–427. 8 indexed citations
19.
Soria, Jean‐Charles, C. Massard, Nicolas Magné, et al.. (2009). Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. European Journal of Cancer. 45(13). 2333–2341. 65 indexed citations
20.
Wilding, George, Edwin M. Posadas, Mitchell E. Gross, et al.. (2008). Dasatinib in patients with hormone-refractory progressive prostate cancer: A phase II study. Journal of Clinical Oncology. 26(15_suppl). 5156–5156. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniela Bärtschi Breakdown of academic impact, for papers by Susan M. Flick Breakdown of academic impact, for papers by Stephen Brincat Breakdown of academic impact, for papers by Yasuo Kodera Breakdown of academic impact, for papers by So Young Rha Breakdown of academic impact, for papers by Arya Mariam Roy Breakdown of academic impact, for papers by T. Christopher Windham Breakdown of academic impact, for papers by Jason L. Rowand Breakdown of academic impact, for papers by Magdalena Benetkiewicz Breakdown of academic impact, for papers by Stefan Paul Moenig
Rankless by CCL
2026